← Leaderboards
Hagen Cramer
Gemini Technologies, Inc.
$1,211,017
Attributed
$1,211,017
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,211,017 · 4
By mechanism
R44$750,000 · 1
R43$461,017 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Antisense Nucleic Acid”
- Jeffrey S Glenn · Stanford University$8,915,196
- Ke Zhang · Northeastern University$7,536,805
- Luciano A Marraffini · Rockefeller University$5,932,500
- Charles A Thornton · Virginia Commonwealth University$5,654,221
- David R. Corey · University Of Texas Sw Med Ctr/Dallas$5,651,763
- Michael G Rosenfeld · University Of California, San Diego$5,595,046
Research focus
Antisense Nucleic AcidTissue /Cell CultureDrug Design /Synthesis /ProductionBiotherapeutic AgentEndoribonucleasesEnzyme ActivityPharmacokineticsPolymerase Chain ReactionRespiratory Disorder ChemotherapyRespiratory Syncytial VirusCercopithecidaeHigh Performance Liquid ChromatographyInhalation Drug AdministrationLaboratory RatVirus ReplicationAntiviral AgentsAdenine NucleotidesDrug Screening /EvaluationChemical SynthesisNonhuman Therapy EvaluationSevere Acute Respiratory SyndromeTechnology /Technique DevelopmentTelomeraseVirus Rna
Grant awards (5)
2-5A Antisense for Degradation of SARS Coronavirus RNA$189,967
R43 · FY2004 · AI
Screening for Rnase L Activators$133,322
R43 · FY2004 · CA
Increasing 2-5A effectiveness through better chemistry$137,728
R43 · FY2003 · CA
2-5A ANTISENSE INHIBITION OF RESPIRATORY SYNCTIAL VIRUS$324,500
R44 · FY2001 · AI
2-5A ANTISENSE INHIBITION OF RESPIRATORY SYNCTIAL VIRUS$425,500
R44 · FY2000 · AI